Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire
- PMID: 33625686
- PMCID: PMC7903365
- DOI: 10.1007/s43440-021-00235-1
Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire
Abstract
Background: The benefits of corticosteroids for the treatment of COVID-19 infection are documented in the literature. The goal of the study is to compare the severity of rhinological symptoms of COVID-19 between patients with nasal steroid use (NSU) and the control group (CG) using the sino-nasal outcome test (SNOT-22) questionnaire.
Methods: A face-to-face survey was conducted at a second referral state hospital between. Patients with a complete recovery from COVID-19 were included in NSU and CG groups. Two subscales of the SNOT-22 were filled by the patients. The frequency and duration of smell and taste loss and SNOT-22 scores were compared between the two groups.
Results: Forty-seven patients were included in the study. Thirty-one patients were in CG and 16 patients in the NSU group. Twenty-four (51.1%) patients were females and 23 (48.9%) were males. The mean age was 41.4 ± 8.6 years. Olfactory dysfunction was detected in 12 (75%) patients in the NSU group, and 31 (93.3%) patients in the control group (CG). Gustatory dysfunction was seen in 10 (62.5%) patients in the NSU group and 24 (77.4%) patients NSU group. (p = 0.071, 0.279, respectively). The duration of the olfactory (6.6 ± 2.5 days) and gustatory dysfunction (6.1 ± 2.6 days) and the mean SNOT-22 total score (11.9 ± 1.6) was significantly lower in the NSU group (p < 0.001, CI 11.1-5.1, CI 9.9-4.6, CI 9.3-5.9, respectively).
Conclusions: Although nasal steroid use does not prevent olfactory and gustatory dysfunction in COVID-19 patients, it may reduce the severity and duration of these symptoms.
Keywords: COVID-19; Gustatory dysfunction; Nasal steroids; SNOT-22; allergic rhinitis; olfactory dysfunction.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019.JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):723-728. doi: 10.1001/jamaoto.2020.1155. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 32556070 Free PMC article.
-
Olfactory and Gustatory Dysfunctions as a Clinical Manifestation of Coronavirus Disease 2019 in a Malaysian Tertiary Center.Ann Otol Rhinol Laryngol. 2021 May;130(5):513-519. doi: 10.1177/0003489420963165. Epub 2020 Oct 7. Ann Otol Rhinol Laryngol. 2021. PMID: 33025798
-
COVID-19 Viral Load in the Severity of and Recovery From Olfactory and Gustatory Dysfunction.Laryngoscope. 2020 Nov;130(11):2680-2685. doi: 10.1002/lary.29056. Epub 2020 Sep 8. Laryngoscope. 2020. PMID: 32794209 Free PMC article.
-
Olfactory and gustatory dysfunctions in COVID-19 patients: A systematic review and meta-analysis.Asian Pac J Allergy Immunol. 2020 Sep;38(3):162-169. doi: 10.12932/AP-210520-0853. Asian Pac J Allergy Immunol. 2020. PMID: 32563232
-
Therapeutic use of steroids in non-chronic rhinosinusitis olfactory dysfunction: a systematic evidence-based review with recommendations.Int Forum Allergy Rhinol. 2019 Feb;9(2):165-176. doi: 10.1002/alr.22240. Epub 2018 Nov 24. Int Forum Allergy Rhinol. 2019. PMID: 30472771
Cited by
-
Can the Nasal Cavity Help Tackle COVID-19?Pharmaceutics. 2021 Oct 3;13(10):1612. doi: 10.3390/pharmaceutics13101612. Pharmaceutics. 2021. PMID: 34683904 Free PMC article. Review.
-
Impact of COVID-19 versus chronic rhinosinusitis/rhinitis associated olfactory dysfunction on health utility and quality of life.Laryngoscope Investig Otolaryngol. 2022 Sep 24;7(5):1299-307. doi: 10.1002/lio2.921. Online ahead of print. Laryngoscope Investig Otolaryngol. 2022. PMID: 36249088 Free PMC article.
-
Mechanism and treatment of olfactory dysfunction caused by coronavirus disease 2019.J Transl Med. 2023 Nov 17;21(1):829. doi: 10.1186/s12967-023-04719-x. J Transl Med. 2023. PMID: 37978386 Free PMC article. Review.
-
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013876. doi: 10.1002/14651858.CD013876.pub3. Cochrane Database Syst Rev. 2022. PMID: 36062970 Free PMC article.
-
Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013877. doi: 10.1002/14651858.CD013877.pub3. Cochrane Database Syst Rev. 2022. PMID: 36063364 Free PMC article.
References
-
- Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–2261. doi: 10.1007/s00405-020-05965-1. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical